ARTL
Artelo BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical readout or strategic licensing within ~12 months reduces development risk and limits dilution, enabling a meaningful re-rating toward low-single-digit per-share levels.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical trial failure or disappointing readout
Momentum
1
Value
41
Sentiment
57
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.42 · Bull $3.00 · Bear $0.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-03 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum1 · Δ7d -0.8
Value41 · Δ7d +0.1
Sentiment57 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
1
34% active weight
Current posture
7d trendFlat
Δ7d
-0.8
Δ21d
-96.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
57
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 1.1 / Value 41.1 / Sentiment 56.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$4.98M
Beta
1.11
Shares Out
2.02M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.18
Rev YoY
-
EPS YoY
-88.4%
Gross Margin
-
Op Margin
-
Net Debt
-$2.34M
Current Ratio
0.38
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology